Lo studio sarà presentato al congresso Stresa Headache 2019
di V. Tullo, M. Curone, B. Colombo, G. Allais, D. Zarcone, M. G. Saracco, G. Bussone
Our study has demonstrated the efficacy of Kuzik® in the improvement of episodic MO with a reduction at least of 50% in the frequency of attacks per month (51%) and in MIDAS disability score (84%). Kuzik® was well tolerated and allowed a reduction of 50% of symptomatic drug assumptions in 43% of patients treated.
On the basis of these data, we suggest that the use of Kuzik® may have a role in the prophylactic treatment of MO.